Search terms
Results 1 - 10 of 32 - ordered by :
Pages: 1 2 3 4

Introduction Despite the same electrophysiological abnormality, the risk of stroke and systemic embolism in atrial fibrillation (AF) ranges from <1%/year to >20%/year and can be assessed by simple ...

European Heart Journal, CURRENT OPINION, Raffaele De Caterina, A. John Camm

Date : 14/12/2014 Item size : 431415 bytes

The 15 topics are (i) practical start-up and follow-up scheme for patients on NOACs; (ii) how to measure the anticoagulant effect of NOACs; (iii) drugdrug interactions and pharmacokinetics of NOACs; ...

Europace, EHRA PRACTICAL GUIDE, Hein Heidbuchel, Peter Verhamme, Marco Alings, Matthias Antz, Hans-Christoph Diener, Werner Hacke, Jonas Oldgren, Peter Sinnaeve, A. John Camm, Paulus Kirchhof

Date : 01/10/2015 Item size : 1118485 bytes

Abstract Aims Although non-vitamin K antagonist oral anticoagulants are recommended for stroke prevention in patients with non-valvular atrial fibrillation (NVAF) based on clinical trial results, ...

European Heart Journal, FASTTRACK ESC Clinical Registry, A. John Camm, Pierre Amarenco, Sylvia Haas, Susanne Hess, Paulus Kirchhof, Silvia Kuhls, Martin van Eickels, Alexander G.G. Turpie

Date : 07/04/2016 Item size : 258982 bytes

Preamble Guidelines summarize and evaluate all currently available evidence on a particular issue with the aim of assisting physicians in selecting the best management strategy for an individual ...

Europace, ESC GUIDELINES, Authors/Task Force Members, A. John Camm, Gregory Y.H. Lip, Raffaele De Caterina, Irene Savelieva, Dan Atar, Stefan H. Hohnloser, Gerhard Hindricks, Paulus Kirchhof, ESC ...

Date : 01/10/2012 Item size : 1008256 bytes

Furthermore, strokes associated with AF result more often in death or permanent disability than strokes that occur as a result of other aetiologies.69 The presence of AF is also associated with a ...

Europace, TASK FORCE, Paulus Kirchhof, Jeroen Bax, Carina Blomstrom-Lundquist, Hugh Calkins, A. John Camm, Ricardo Cappato, Francisco Cosio, Harry Crijns, Hans-Christian Diener, Andreas Goette, ...

Date : 01/07/2009 Item size : 1103340 bytes

Abstract Aims We compared patient-reported treatment satisfaction and the economic impact of anticoagulation therapy with rivaroxaban vs. vitamin K antagonists (VKAs) in patients with non-valvular ...

Europace, CLINICAL RESEARCH, Stefan H. Hohnloser, Riccardo Cappato, Michael D. Ezekowitz, Thomas Evers, Kurtulus Sahin, Paulus Kirchhof, Isabelle Ling Meng, Martin van Eickels, A. John Camm

Date : 01/02/2016 Item size : 212810 bytes

Current challenges in atrial fibrillation management and resulting research questions The increase in life expectancy and recent improvements in treatment of acute heart disease have resulted in a ...

Europace, SPECIAL REPORT, Ulrich Schotten, Stephane Hatem, Ursula Ravens, Pierre Jaïs, Frank-Ulrich Müller, Andres Goette, Stephan Rohr, Gudrun Antoons, Burkert Pieske, Daniel Scherr, Ali Oto, ...

Date : 01/10/2015 Item size : 290815 bytes

With increasing operator experience, successful and event-free device implantation is achieved in typically 97% of the cases. [...]in non-randomized cohorts implanted with LAA occlusion devices, ...

Europace, Review, Thorsten Lewalter, Réda Ibrahim, Bert Albers, A. John Camm

Date : 01/05/2013 Item size : 186498 bytes

The meta-analysis emphasises the need for a well-designed large-scale clinical trial to firmly establish the safety and efficacy of dabigatran and other NOACs in peri-procedural management of ...

Europace, Ablation for atrial fibrillation, Stefan H. Hohnloser, A. John Camm

Date : 01/10/2013 Item size : 181657 bytes

[...]the present meta-analysis of all randomized controlled AF trials of dronedarone was conducted for three purposes: (i) to summarize the totality of data on the efficacy and safety of dronedarone ...

Europace, CLINICAL RESEARCH, Stefan H. Hohnloser, Stuart J. Connolly, A. John Camm, Jonathan L. Halperin, David Radzik

Date : 01/08/2014 Item size : 210556 bytes